Table 1.
Baseline characteristics by high and normal PAP/CO slope
| High PAP/CO N=296 | Normal PAP/CO N=418 | P-value | |
|---|---|---|---|
| Age, years | 63 (13) | 52 (16) | <0.001 |
| Women, n (%) | 170 (57) | 252 (60) | 0.58 |
| Body-mass index, kg/m2 | 29.1 (6.1) | 29.2 (6.7) | 0.79 |
| Hypertension, n (%) | 184 (62) | 189 (45) | <0.001 |
| Diabetes mellitus, n (%) | 65 (22) | 50 (12) | <0.001 |
| Current smoker, n (%) | 12 (4) | 10 (2) | 0.21 |
| Past/present smoker, n (%) | 149 (53) | 131 (33) | <0.001 |
| Pulmonary arterial hypertension, n (%) | 8 (3) | 6 (1) | 0.24 |
| Prior HFpEF, n (%) | 58 (20) | 29 (7) | <0.001 |
| Myocardial infarction, n (%) | 16 (5) | 13 (3) | 0.13 |
| Interstitial lung disease, n (%) | 38 (13) | 23 (6) | 0.001 |
| COPD, n (%) | 54 (18) | 22 (5) | <0.001 |
| Coronary artery disease , n (%) | 62 (21) | 53 (13) | 0.003 |
| Valve disease, n (%) | 39 (13) | 17 (4) | <0.001 |
| Connective tissue disease, n (%) | 24 (8) | 37 (9) | 0.70 |
| Biomarkers (n=678) | |||
| NT-proBNP, pg/mL median (IQR) | 154 (64, 535) | 52 (26, 127) | <0.001 |
| hsCRP, pg/mL median | 2.5 (1.2, 5.3) | 1.5 (0.6, 3.8) | <0.001 |
| Pulmonary function test (n=671) | |||
| % predicted FEV1, % | 78 (22) | 92 (18) | <0.001 |
| % predicted FVC, % | 84 (20) | 96 (18) | <0.001 |
| % predicted FEV1/FVC, % | 93 (14) | 96 (10) | <0.001 |
| % predicted DLCO, % | 62 (21) | 80 (20) | <0.001 |
| COPD GOLD stage 3*, n (%) | 25 (9) | 6 (2) | <0.001 |
| Severe ILD*, n (%) | 6 (2) | 5 (1) | 0.36 |
*
GOLD stage 3 or greater defined as FEV1/FVC < 70% predicted and FEV1< 50% predicted. ILD defined as FVC <50% pred and DLCO <=35% predicted (33)